NIH-funded scientists shrink CRISPR system for efficient in-body gene therapy

A smaller CRISPR enzyme pushed genome editing closer to a long-sought goal: treating disease inside the body, not only by editing cells outside it. National Institutes of Health-funded researchers reported that a naturally occurring nuclease, Al3Cas12f, was compact enough to fit into adeno-associated virus vectors, then built an enhanced version that sharply improved editing in human cells.

The work, published April 13, 2026, in Nature Structural & Molecular Biology, focused on Alistipes sp. Cas12f, or Al3Cas12f, a miniature enzyme discovered through metagenomics. The team at the University of Texas at Austin, working with collaborators at Metagenomi Therapeutics, engineered a variant called Al3Cas12f RKK. In testing, it lifted editing efficiency from less than 10% to more than 80% across targets and reached 90% in one frequently edited genomic region. The researchers also found that Al3Cas12f forms efficient R-loop formation through a stable dimer interface and a naturally optimized guide RNA.

That advance matters because delivery has been one of the hardest limits in CRISPR medicine. The safest and most accurate editors are often too large to fit into the viral carriers clinicians rely on, especially adeno-associated virus, which has a cargo limit of about 4.7 kilobases, including its inverted terminal repeats. The new enzyme’s compact size gives researchers a better chance of pairing strong editing with a delivery system that is already widely studied in gene therapy. The team compared Al3Cas12f with Oscillibacter sp. Cas12f and Ruminiclostridium herbifermentans Cas12f, using imaging and machine-learning tools to understand why the new enzyme behaved more effectively in human cells.

The medical implications are broad, but the path to patients remains early. The researchers said the technology could eventually help address mutations tied to cancer, atherosclerosis and amyotrophic lateral sclerosis. The next planned step is testing the nuclease when packaged into AAV vectors, a move that would shift the work from a laboratory advance toward a therapy candidate that could operate inside tissues.

The study lands as CRISPR medicine is already moving, slowly, into the clinic. The Food and Drug Administration approved Casgevy on December 8, 2023, as the first FDA-approved therapy to use CRISPR/Cas9, and most approved CRISPR treatments so far have been ex vivo, meaning cells are edited outside the body and then returned. In June 2025, NIH reported the first known personalized CRISPR-based medicine given to a single patient. Even with those milestones, in-body gene editing still faces major safety, regulatory and ethical tests, especially around immune reactions, long-term monitoring and equitable access if these tools ever leave elite research centers and reach routine care.